Your browser doesn't support javascript.
loading
The Validity of the EuroQol Health and Wellbeing Short Version (EQ-HWB-S) Instrument in Parents of Children With and Without Health Conditions.
Bailey, Cate; Dalziel, Kim; Jones, Renee; Hiscock, Harriet; Devlin, Nancy J; Peasgood, Tessa.
Affiliation
  • Bailey C; Melbourne Health Economics, Melbourne School of Population and Global Health, The University of Melbourne, Level 4, 207 Bouverie St, Carlton, VIC, 3053, Australia. cate.bailey@unimelb.edu.au.
  • Dalziel K; Melbourne Health Economics, Melbourne School of Population and Global Health, The University of Melbourne, Level 4, 207 Bouverie St, Carlton, VIC, 3053, Australia.
  • Jones R; Melbourne Health Economics, Melbourne School of Population and Global Health, The University of Melbourne, Level 4, 207 Bouverie St, Carlton, VIC, 3053, Australia.
  • Hiscock H; Health Services and Economics, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
  • Devlin NJ; Health Services Research Unit, Royal Children's Hospital, Melbourne, VIC, Australia.
  • Peasgood T; Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia.
Pharmacoeconomics ; 42(Suppl 1): 163-179, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38238605
ABSTRACT

BACKGROUND:

 The EuroQol Health and Wellbeing Short Version (EQ-HWB-S) instrument has been developed to measure the health and wellbeing of care-recipients and their caregivers for use in economic evaluation.The EQ-HWB-S has nine items, and pilot UK preference weights have now been developed.

OBJECTIVE:

We aimed to investigate the validity of the instrument in parents of children with and without health conditions.

METHODS:

EQ-HWB-S data were sourced from an Australian paediatric multi-instrument comparison study. We analysed the baseline characteristics and response distribution of the EQ-HWB-S items. Assessment of known-group validity was conducted for EQ-HWB-S items, level sum-scores and preference-weighted scores, including partial effects. Known-group analyses included three child health variables and where caregivers reported coronavirus disease 2019 (COVID-19) had impacted their wellbeing. We included analyses across gender, controlled for child and parent demographic variables, and compared scores across child health conditions.

RESULTS:

 Item responses were distributed as expected, with higher skew for mobility and activities. Parents experienced high levels of exhaustion. We detected significant differences between groups for level sum-scores and preference-weighted scores, as hypothesised; all tests were significant (p < 0.001), with moderate effect sizes (effect sizes were slightly higher for female than male parents). The regression analysis identified significantly different EQ-HWB-S scores for child health samples compared with the general population after controlling for demographic variables. Differences were observed between child health conditions.

CONCLUSION:

The EQ-HWB-S is a useful instrument to measure parent quality of life for economic evaluation in this population. Data were limited to one time point; further research should investigate the instrument's sensitivity to change and test-retest reliability in this population.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parents / Quality of Life / Health Status / COVID-19 Type of study: Prognostic_studies Aspects: Patient_preference Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Country/Region as subject: Oceania Language: En Journal: Pharmacoeconomics Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2024 Document type: Article Affiliation country: Australia Country of publication: New Zealand

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parents / Quality of Life / Health Status / COVID-19 Type of study: Prognostic_studies Aspects: Patient_preference Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Country/Region as subject: Oceania Language: En Journal: Pharmacoeconomics Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2024 Document type: Article Affiliation country: Australia Country of publication: New Zealand